Investigational New Drugs

, Volume 30, Issue 4, pp 1628–1640

Feasibility and effectiveness of inhaled carboplatin in NSCLC patients

  • Paul Zarogoulidis
  • Ellada Eleftheriadou
  • Iordanis Sapardanis
  • Vasiliki Zarogoulidou
  • Helliel Lithoxopoulou
  • Theodoros Kontakiotis
  • Nikolaos Karamanos
  • George Zachariadis
  • Maria Mabroudi
  • Athanasios Zisimopoulos
  • Kostantinos Zarogoulidis
PHASE II STUDIES

Summary

Background Inhaled chemotherapy is under investigation as an alternative therapeutic modality for Non-Small Cell Lung Cancer. Methods 60 NSCLC patients were randomized into 3 groups in this study. 20/60 patients (group A—control group) received I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1); 20/60 (group B) received 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1); and 20/60 (group C) received all the predicted I.V. dose of carboplatin as aerosol in 3 equally divided fractions D1-3. In all patients I.V. docetaxel 100/m2 was as well administered (D1). Lung functional tests were performed in all groups before chemotherapy in the 3rd and 6th cycles. Results Group B had a statistically significant increase in survival compared to control group A [275 days (95% CI 249–300) vs. 211 (95% CI 185–236)]. In regard to lung functional tests, a statistically significant decline was observed only in FEV1 of group C in 6 months compared to the initial measurement. Conclusions Inhaled carboplatin could be given as an alternative root of pulmonary drug delivery in selected patients, but further randomized studies remain to prove whether the inhaled chemotherapy is an efficient and safe treatment modality.

Keywords

NSCLC Inhaled chemotherapy Experimental chemotherapy regimens Carboplatin 

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107 CrossRefPubMedGoogle Scholar
  2. 2.
    Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122(3):1037–1057. doi:10.1378/chest.122.3.1037 CrossRefPubMedGoogle Scholar
  3. 3.
    Stewart LA, Pignon JP (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899–909CrossRefGoogle Scholar
  4. 4.
    Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MK, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P, Big Lung Trial Participants (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59(10):828–836. doi:10.1136/thx.2003.020164 CrossRefPubMedGoogle Scholar
  5. 5.
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9(9):1618–1626PubMedGoogle Scholar
  6. 6.
    Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K, Hasegawa Y (1999) Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res 90(2):249–253CrossRefPubMedGoogle Scholar
  7. 7.
    Peng H, Ma M, Han B (2011) Survival analysis of 1,742 patients with stage IV non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14(4):362–366. doi:10.3779/j.issn.1009-3419.2011.04.11 PubMedGoogle Scholar
  8. 8.
    Richter Larsen K, Svendsen UG, Milman N, Brenøe J, Petersen BN (1997) Exercise testing in the preoperative evaluation of patients with bronchogenic carcinoma. Eur Respir J 10(7):1559–1565. doi:10.1183/09031936.97.10071559 CrossRefPubMedGoogle Scholar
  9. 9.
    Jones LW, Eves ND, Kraus WE, Potti A, Crawford J, Blumenthal JA, Peterson BL, Douglas PS (2010) The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer 10:155. doi:10.1186/1471-2407-10-155 CrossRefPubMedGoogle Scholar
  10. 10.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non small-cell lung cancer. N Engl J Med 346:92–98CrossRefPubMedGoogle Scholar
  11. 11.
    Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG (2001) Development of inhalational agents for oncologic use. J Clin Oncol 19:1839–1847PubMedGoogle Scholar
  12. 12.
    Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592. doi:10.1038/nrc1893 CrossRefPubMedGoogle Scholar
  13. 13.
    Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395–1403. doi:10.1200/JCO.2005.03.8166 CrossRefPubMedGoogle Scholar
  14. 14.
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43CrossRefPubMedGoogle Scholar
  15. 15.
    Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H (2004) Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 22:27–37. doi:10.1007/s11060-005-7411-y CrossRefPubMedGoogle Scholar
  16. 16.
    Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402PubMedGoogle Scholar
  17. 17.
    Robinson WR, Coberly C, Beyer J, Lewis A, Ballard C (2008) Office-based intraperitoneal chemotherapy for ovarian cancer. J Oncol Pract 4(5):225–228. doi:10.1200/JOP.0858503 CrossRefPubMedGoogle Scholar
  18. 18.
    Hofstra LS, Bos AM, de Vries EG, van der Zee AG, Beijnen JH, Rosing H, Mulder NH, Aalders JG, Willemse PH (2001) A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer 85(11):1627–1633. doi:10.1054/bjoc.2001.2161 CrossRefPubMedGoogle Scholar
  19. 19.
    Foote RL, Kasperbauer JL, Okuno SH, Nichols DA, Olsen KD, Brown PD, Garces YI, Sargent DJ, Strome SE (2005) A pilot study of high-dose intra-arterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer 103(3):559–568. doi:10.1002/cncr.20803 CrossRefPubMedGoogle Scholar
  20. 20.
    Osaki T, Hanagiri T, Nakanishi R, Yoshino I, Taga S, Yasumoto K (1999) Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study. Chest 115:1424–1428. doi:10.1378/chest.115.5.1424 CrossRefPubMedGoogle Scholar
  21. 21.
    Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl JMed 335(26):1950–1955CrossRefGoogle Scholar
  22. 22.
    Labiris NR, Dolovich MB (2003) Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588–599. doi:10.1046/j.1365-2125.2003.01892.x CrossRefPubMedGoogle Scholar
  23. 23.
    Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R (2002) Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 23:1625–1631. doi:10.1053/euhj.2002.3328 CrossRefPubMedGoogle Scholar
  24. 24.
    Markman M, Cleary S, Pfeifle C, Howell SB (1986) Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 58:18–21. doi:10.1002/1097-0142(19860701)58:1<18::AID-CNCR2820580105>3.0.CO;2-C CrossRefPubMedGoogle Scholar
  25. 25.
    Markman M (1996) Intraperitoneal therapy of ovarian cancer. Oncologist 1:18–21PubMedGoogle Scholar
  26. 26.
    Rusch VW, Figlin R, Godwin D, Piantadosi S (1991) Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9:313–319PubMedGoogle Scholar
  27. 27.
    Okuyama S, Matsumotos K, Saijo H, Suetake M, Yuasa R, Mishina H (1993) Reinforcing aerosol cisplatin for radiotherapy of laryngeal cancer. Tohoku J Exp Med 169(3):253–255CrossRefPubMedGoogle Scholar
  28. 28.
    Duvillard C, Romanet P, Cosmidis A, Beaudouin N, Chauffert B (2004) Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Ann Otol Rhinol Laryngol 113:229–333PubMedGoogle Scholar
  29. 29.
    Goldberg EP, Hadba AR, Almond BA, Marotta JS (2002) Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 54:159–180. doi:10.1211/0022357021778268 CrossRefPubMedGoogle Scholar
  30. 30.
    Tatsumura T, Yamamoto K, Murakami A, Tsuda M, Sugiyama S (1983) New chemotherapeutic method for the treatment of tracheal and bronchial cancers G nebulization chemotherapy. Gan No Rinsho 29:765–770PubMedGoogle Scholar
  31. 31.
    Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S (1993) Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 68:1146–1149CrossRefPubMedGoogle Scholar
  32. 32.
    Gautam A, Koshkina N (2003) Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 3:287–296CrossRefPubMedGoogle Scholar
  33. 33.
    Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, Imondi AR, Vail DM (1999) Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 5(9):2653–2659PubMedGoogle Scholar
  34. 34.
    Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V (2004) Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 17(1):7–14. doi:10.1089/089426804322994415 CrossRefPubMedGoogle Scholar
  35. 35.
    Minchin RF, Johnston MR, Aiken MA, Boyd MR (1984) Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J Pharmacol Experim Therap 229(1):193–198Google Scholar
  36. 36.
    Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR (2010) Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 16(8):2466–2473. doi:10.1158/1078-0432.CCR-09-3015 CrossRefPubMedGoogle Scholar
  37. 37.
    Wittgen BPH, Kunst PWA, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Peters GJ, Postmus PE (2007) Phase I Study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 13(8):2414–2421. doi:10.1158/1078-0432.CCR-06-1480 CrossRefPubMedGoogle Scholar
  38. 38.
    Selting K, Waldrep JC, Reinero C, Branson K, Gustafson D, Kim DY, Henry C, Owen N, Madsen R, Dhand R (2008) Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe® intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv 21(3):255–268. doi:10.1089/jamp.2008.0684 CrossRefPubMedGoogle Scholar
  39. 39.
    Khanna C, Vail DM (2003) Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets 3(4):265–273CrossRefPubMedGoogle Scholar
  40. 40.
    Kleinstreuer C, Zhang Z, Donohue JF (2008) Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 10:195–220. doi:10.1146/annurev.bioeng.10.061807.160544 CrossRefPubMedGoogle Scholar
  41. 41.
    Laube BL (2005) The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 50:1161–1176PubMedGoogle Scholar
  42. 42.
    Zarogoulidis P, Papanas N, Kouliatsis G, Spyratos D, Zarogoulidis K, Maltezos E (2011) Inhaled insulin: too soon to be forgotten? J Aerosol Med Pulm Drug Deliv. doi:10.1089/jamp.2011.0876 [Epub ahead of print]
  43. 43.
    Shevchenko IT, Resnik GE (1968) Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer. Neoplasma 15:419–426PubMedGoogle Scholar
  44. 44.
    Camus P, Fanton A, Bonniaud P, Camus C, Foucher P (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71:301–326. doi:10.1159/000079633 CrossRefPubMedGoogle Scholar
  45. 45.
    Camus P (2004) Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer 91(Suppl 2):S1–S2. doi:10.1038/sj.bjc.6602060 CrossRefPubMedGoogle Scholar
  46. 46.
    Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L (2002) Quality of life of long-term survivors of non-small-cell lung cancer. J Clin Oncol 20:2920–2929. doi:10.1200/JCO.2002.09.045 CrossRefPubMedGoogle Scholar
  47. 47.
    Moore MJ, Erlichman C (1998) Pharmacology of anticancer drugs. In: Tannock IF, Hill RP (eds) The basic science of oncology, 3rd edn. McGraw-Hill Health Professions Division, New York, pp 370–391Google Scholar
  48. 48.
    Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) ATS/ERS Task Force: standardisation of spirometry. Eur Respir J 26(2):319–338. doi:10.1183/09031936.00130010 CrossRefPubMedGoogle Scholar
  49. 49.
    ICH HARMONISED TRIPARTITE GUIDELINE (1995) Published in the Federal Register, Vol. 60, No. 40, p. 11264–11268, 1 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S3A/Step4/S3A_Guideline.pdf
  50. 50.
    WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI. Ethical Principles for Medical Research Involving Human Subjects http://www.wma.net/en/30publications/10policies/b3/17c.pdf
  51. 51.
    Krilov LR (2002) Safety issues related to the administration of ribavirin. Pediatr Infect Dis J 21:479–481CrossRefPubMedGoogle Scholar
  52. 52.
    Ros JJ, Langen MC, Stallen PC, Lenderink AW (1996) Pentamidine aerosols and environmental contamination: health-care workers at risk. Pharm World Sci 18:148–152CrossRefPubMedGoogle Scholar
  53. 53.
    Wahlin B, Malmstrom B, Soop M, Hellstrom LG (1996) A paediatric canopy system for aerosol administration and minimized environmental pollution. Acta Anaesthesiol Scand 40:932–939CrossRefPubMedGoogle Scholar
  54. 54.
    Chou AJ, Bell MD, Mackinson C, Gupta R, Meyers PA, Gorlick R (2007) Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. J Clinical Oncology. ASCO Annual Meeting Proceedings Part I, 25(18Suppl):9525Google Scholar
  55. 55.
    Geller DS, Gorlick R (2010) Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8(10):705–718PubMedGoogle Scholar
  56. 56.
    Morrow PE. Conference on the scientific basis of respiratory therapy. Aerosol therapy. Aerosol characterization and deposition. Am Rev Respir Dis 110:88–99Google Scholar
  57. 57.
    ICH HARMONISED TRIPARTITE GUIDELINE SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A (2000) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
  58. 58.
    Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lemarie E (2008) Aerosolized chemotherapy. J Aerosol Med Pulm Drug Delivery 21(1):61–70. doi:10.1089/jamp.2007.0656 CrossRefGoogle Scholar
  59. 59.
    Lipworth BJ (1996) Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 42(6):697–705. doi:10.1046/j.1365-2125.1996.00493.x CrossRefPubMedGoogle Scholar
  60. 60.
    Laube BL (2005) The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 50(9):1161–1176PubMedGoogle Scholar
  61. 61.
    Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0.June 1, 1999. http://ncictephelp@ctep.nci.nih.gov
  62. 62.
    Gavini E, Manunta L, Giua S, Achenza G, Giunchedi P (2005) Spray-dried poly(D,L-lactide) microspheres containing carboplatin for veterinary use: in vitro and in vivo studies. AAPS PharmSciTech 20;6(1):E108-E114. doi: 10.1208/pt060117 Google Scholar
  63. 63.
    Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D (2000) Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharmaceut Biomed Anal (24):1–10. doi:10.1016/S0731-7085(00)00377-0
  64. 64.
    Tibben MM, Rademaker-Lakhai JM, Rice JR, Stewart DR, Schellens JHM, Beijnen JH (2002) Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. Anal Bioanal Chem 373:233–236. doi:10.1007/s00216-002-1340-9 CrossRefPubMedGoogle Scholar
  65. 65.
    Villarino N, Cox S, Yarbrough J, Martín-Jiménez T (2010) Determination of carboplatin in canine plasma by high-performance liquid chromatography. Biomed Chromatogr 24(8):908–913. doi:10.1002/bmc.1385 PubMedGoogle Scholar
  66. 66.
    Trotti A, Byhardt R, Stetz J, Corn B, Fu K, Gunderson L, McCormick B, Morris M, Tyvin Rich, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol* Biol* Phys (IJROBP) 47(1):13–47. doi:10.1016/S0360-3016(99)00559-3 CrossRefGoogle Scholar
  67. 67.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwart LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026 CrossRefPubMedGoogle Scholar
  68. 68.
    Wang Z, Chen HT, Roa W, Finlay W (2003) Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharm Sci 6:95–100PubMedGoogle Scholar
  69. 69.
    Yancik R (1997) Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80(7):1273–1283. doi:10.1002/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4 CrossRefPubMedGoogle Scholar
  70. 70.
    Piepoli MF, Davos C, Francis DP, Coats AJ, ExTraMATCH Collaborative (2004) Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 328(7433):189. doi:10.1136/bmj.37938.645220.EE CrossRefPubMedGoogle Scholar
  71. 71.
    International Commission on Radiological Protection (1994) Human respiratory tract model for radiological protection. Elsevier Science Ltd; ICRP Publication 66; Ann. ICRP 24(1/3), OxfordGoogle Scholar
  72. 72.
    Clay MM, Pavia D, Newman SP, Clarke SW (1983) Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 38(10):755–759CrossRefPubMedGoogle Scholar
  73. 73.
    Khalid MN, Simard P, Hoarau D, Dragomir A, Leroux JC (2006) Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res 23(4):752–758. doi:10.1007/s11095-006-9662-5 CrossRefPubMedGoogle Scholar
  74. 74.
    Hitzman CJ, Wattenberg LW, Wiedmann TS (2006) Pharmacokinetics of 5-Fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci 95:1196–1211. doi:10.1002/jps.20607 CrossRefPubMedGoogle Scholar
  75. 75.
    Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, Kempf M, Racineux JL, Diot P, Benoit JP, Urban T (2009) Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharmac Biopharmac 73(2):239–246. doi:10.1016/j.ejpb.2009.06.013 CrossRefGoogle Scholar
  76. 76.
    Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7(10):3258–3262PubMedGoogle Scholar
  77. 77.
    Ajay G, Nadezhda K (2003) Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 3:287–296CrossRefGoogle Scholar
  78. 78.
    Utsuki T, Brem H, Pitha J, Loftsson T, Kristmundsdottir T, Tyler BM, Olivi A (1996) Potentiation of anticancer effects of microencapsulated carboplatin by hydroxypropyl α-cyclodextrin. J Contr Release 40(3):251–260. doi:10.1016/0168-3659(95)00192-1 CrossRefGoogle Scholar
  79. 79.
    Chen W, Lu DR (1999) Carboplatin-loaded PLGA microspheres for intracerebral injection: formulation and characterization. J Microencapsul 16(5):551–563. doi:10.1080/026520499288753 CrossRefPubMedGoogle Scholar
  80. 80.
    Stegen K, Neujens A, Crombez G, Hermans D, Van de Woestijne KP, Van den Bergh O (1998) Negative effect, respiratory reactivity, and somatic complaints in a CO2 enriched air inhalation paradigm. Biol Psychol 49(1–2):109–122CrossRefPubMedGoogle Scholar
  81. 81.
    Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC (2001) Improved respiratory delivery of the anticancer drugs, camptothecin and Paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 47(5):451–456CrossRefPubMedGoogle Scholar
  82. 82.
    Newsom Davis J, Stagg D (1975) Interrelationships of the volume and time components of individual breaths in resting man. J Physiol 245:481–498Google Scholar
  83. 83.
    Usmani OS, Barnes PJ (2011) The small airways: an important target in asthma and COPD treatment. Respir Dis Pract 21:1–4. doi:10.3109/07853890.2011.585656 Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Paul Zarogoulidis
    • 1
  • Ellada Eleftheriadou
    • 1
  • Iordanis Sapardanis
    • 1
  • Vasiliki Zarogoulidou
    • 1
  • Helliel Lithoxopoulou
    • 1
  • Theodoros Kontakiotis
    • 2
  • Nikolaos Karamanos
    • 3
  • George Zachariadis
    • 4
  • Maria Mabroudi
    • 1
  • Athanasios Zisimopoulos
    • 5
  • Kostantinos Zarogoulidis
    • 1
  1. 1.Aristotle University Pulmonary Department“G. Papanikolaou” HospitalThessalonikiGreece
  2. 2.Bronchoscopic Unit“G. Papanikolaou” HospitalThessalonikiGreece
  3. 3.Laboratory of BiochemistryUniversity of PatrasPatrasGreece
  4. 4.Laboratory of Analytical Chemistry, Department of ChemistryAristotle University of ThessalonikiThessalonikiGreece
  5. 5.Nuclear Medicine DepartmentDemocritus University of ThraceAlexandroupolisGreece

Personalised recommendations